arrow
B

Bhuvaneswari Ramaswamy

The Ohio State University
H指数:45
被引数:7,401

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Changes in Glucose level During Chemotherapy Treatment in Patients With Stage I–IV Breast Cancer

化疗期间不同阶段(I–IV期)乳腺癌患者血糖水平的变化

2025-05-270
PRE
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer

MEK抑制剂曲美替尼单独或与AKT抑制剂GSK2141795/乌普罗替尼联合治疗转移性三阴性乳腺癌患者的II期研究

2024-12-071
PRE
Novel Metrics of HER2 Heterogeneity in HER2Positive and HER2-Low Breast Cancer via High Dimensional Multiplexed Immunofluorescence Spatial Profiling
2024-05-020
PRE
Phase II study of trametinib alone and in combination with uprosertib in patients with metastatic triple negative breast cancer previously treated with chemotherapy: OSU 13317
2024-03-220
PRE
Final survival outcomes and post-hoc tumor gene expression pathway analyses of complete responders from a phase Ib clinical trial of HSP90 inhibitor onalespib and paclitaxel in patients with advanced triple-negative breast cancer
2024-03-220
PRE
Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer
2023-12-251
OAAI
Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls

新辅助化疗在局部晚期炎性乳腺癌 (IBC) 治疗中的生存结果与匹配对照组比较

BREAST
IF7.9
2023-12-013
OAAI
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
2023-06-240
OAAI
Worry and Mindfulness Differentially Impact Symptom Burden Following Treatment Among Breast Cancer Survivors: Findings From a Randomized Crossover Trial
2023-06-012
PRE
Single-cell immunoprofiling and spatial analysis of hormone receptor subtypes in HER2+and HER2low breast tumors using multiplexed immunofluorescence
2023-04-040
PRE